ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Decision analysis"

  • Abstract Number: 1298 • 2017 ACR/ARHP Annual Meeting

    Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation

    Tayseer Haroun1, Amanda M. Eudy2,3,4,5, Malithi Jayasundara2, W. Benjamin Nowell6,7, Jeffrey R. Curtis8, Charlotte Whitney White9, Rachelle Crow-Hercher9, Seth D. Ginsberg10 and Megan E. B. Clowse4,11, 1Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, 2Rheumatology, Duke University Medical Center, Durham, NC, 3Duke University, Durham, NC, 4Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 5Duke University Medical Center, Chapel Hill, NC, 6CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, 7Global Healthy Living Foundation, Upper Nyack, NY, 8Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Arthritis Power, Upper Nyack, NY, 10Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, 11Duke University Medical Center, Durham, NC

    Background/Purpose: With new data demonstrating medication compatibility in pregnancy and lactation, it is important to understand how this information can best reach patients. We sought…
  • Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium

    The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA

    Joost Swart1, Nico Wulffraat2, Sytze de Roock3 and Pieter van Dijkhuizen4, 1Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, 2Wilhelmina Children’s Hospital, Utrecht, Netherlands, 3Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…
  • Abstract Number: 779 • 2015 ACR/ARHP Annual Meeting

    Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context

    Haiyan Qu1, Jinoos Yazdany2, W. Winn Chatham3, Ricahrd Shewchuk4 and Jasvinder A. Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of California, San Francisco, San Francisco, CA, 3Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4University fo Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Our objective was to derive a cognitive map of how stakeholders perceive patient-identified facilitators to establish a theoretical framework for the purpose of developing…
  • Abstract Number: 2104 • 2015 ACR/ARHP Annual Meeting

    Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks

    Nick Bansback1,2, Mark Harrison3, William G Dixon4 and Paul Han5, 1Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, 2School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, 3Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, 4Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 5Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME

    Background/Purpose: Doctors and patients make treatment decisions after weighing benefits and harms. For harms, while people prefer treatments with smaller risks, how they react to…
  • Abstract Number: 2269 • 2015 ACR/ARHP Annual Meeting

    Rheumatologists Consider Patient Preferences and Costs When Choosing Treatments for Rheumatoid Arthritis (RA) Patients. a Cross-European Discrete Choice Experiment

    Monika Hifinger1, Mickaël Hiligsmann2, Sofia Ramiro3, Verity Watson4, Johan L. Severens5, Bruno Fautrel6, Loreto Carmona7, Till Uhlig8, Ronald van Vollenhoven9, Peggy Jacques10, Jacqueline Detert11, Carlo Alberto Scirè12, Florian Berghea13, Márta Péntek14, Jose canas Silva15, Andrew Keat16 and Annelies Boonen17, 1Rheumatology, University of Maastricht, Maastricht, Netherlands, 2Department of Health Services Research, University of Maastricht, Maastricht, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, 5Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands, 6Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, 7Instituto de Salud Musculoesqueletica, Madrid, Spain, 8Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 9Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, 10University Hospital Ghent, Ghent, Belgium, 11Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 12Italian Society for Rheumatology, Milan, Italy, 13Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 14Corvinus University of Budapest, Budapest, Hungary, 15Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, 16Northwick Park Hospital, Harrow, United Kingdom, 17Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands

    Background/Purpose: Economic considerations and patient preferences are increasingly important when choosing treatments. It is not known to what extent rheumatologists across Europe account for these…
  • Abstract Number: 2312 • 2015 ACR/ARHP Annual Meeting

    Patient Preferences for Total Knee Replacement Surgery:  Two Year Follow-up  

    Ernest Vina1, Di Ran2, Erin Ashbeck2, Said Ibrahim3, Michael J. Hannon4, Jin Zhou5 and C. Kent Kwoh1, 1Rheumatology, University of Arizona, Tucson, AZ, 2Arthritis Center, University of Arizona, Tucson, AZ, 3Medicine, University of Pennsylvania, Philadelphia, PA, 4Medicine, University of Pittsburgh, Pittsburgh, PA, 5Epidemiology & Biostatistics, University of Arizona, Tucson, AZ

    Background/Purpose: Patients’ preferences for total knee replacement (TKR) may determine actual receipt of TKR and may also change over time.  Yet, no study has longitudinally…
  • Abstract Number: 2329 • 2015 ACR/ARHP Annual Meeting

    Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making

    Mark Harrison1,2, Carlo Marra3 and Nick Bansback4,5, 1Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, 2Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, 3School of Pharmacy, Memorial University, St John's, NF, Canada, 4St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, 5School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Using an example of a new drug for rheumatoid arthritis which offers comparable effectiveness and side-effect point estimates to older drugs, we explore preferences…
  • Abstract Number: 2453 • 2015 ACR/ARHP Annual Meeting

    Evidence-Based Decision Support for Pediatric Rheumatology Reduces Diagnostic Errors, with the Potential to Reduce Capacity Shortage

    Balu Athreya1, Mary Beth Son2, Jonathan S. Hausmann3, Elizabeth Ang4, David Zurakowski5, Michael Segal6 and Robert Sundel7, 1duPont Hospital for Children/Thomas Jefferson University, Wilmington, DE, 2Division of Immunology, Children's Hospital Boston, Boston, MA, 3Rheumatology, Children's Hospital Boston, Boston, MA, 4Paediatrics, University Children's Medical Institute, NUH, Singapore, Singapore, 5Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, 6SimulConsult, Chestnut Hill, MA, 7Immunology, Childrens Hospital, Boston, MA

    Background/Purpose: This projects seeks to respond to the critical shortage of pediatric rheumatologists encapsulating the diagnostic information of the field in an advanced diagnostic decision…
  • Abstract Number: 1310 • 2014 ACR/ARHP Annual Meeting

    Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis

    Maya Gerstein1, Roberto Ezequiel Borgia2, Brian Feldman1, Deborah M. Levy3, Sharon Sukhdeo4, Susanne M. Benseler5, Lawrence W.K. Ng1, Mohamed Abdelhaleem6, Earl D. Silverman2 and Linda T Hiraki7, 1Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 3Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 4Rheumatology, The Hospital For Sick Children, Toronto, ON, Canada, 5Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, 6Department of Paediatric Laboratory Medicine, Division of Haematopathology, The Hospital for Sick Children, Toronto, ON, Canada, 7The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose It can be difficult to differentiate macrophage activation syndrome (MAS) from active pediatric systemic lupus erythematosus (pSLE). However, this differentiation is in determining correct…
  • Abstract Number: 2286 • 2013 ACR/ARHP Annual Meeting

    Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients

    Paul Studenic1, Josef S. Smolen2,3 and Daniel Aletaha4, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2PsAID taskforce, EULAR, Zurich, Switzerland, 32nd Department of Medicine, Krankenhaus Lainz, Vienna, Austria, 4Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria

    Background/Purpose: Patient reported outcomes (PRO) represent an important part of outcomes assessment in rheumatoid arthritis (RA) patients. The Patient Global Assessment (PGA) is an essential…
  • Abstract Number: 107 • 2012 ACR/ARHP Annual Meeting

    Sensitivity to Change of the Ultrasound synovitis  SONAR Score in RA Patients : Results of  the Scqm Cohort

    Pascal Zufferey1, Almut Scherer2, Hans Rudolf Ziswiler3, Giorgio Tamborrini4, Laure Brulhart5 and Burkhard Moeller6, 1Service of Rheumatology, Department of Musculoskeletal Medicine, Lausanne University Hospital, Lausanne, Switzerland, 2SCQM Foundation, Zurich, Switzerland, 3Rheumatology, Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, 4Department of Rheumatology, University Hospital, Zurich, Switzerland, 5service de Rhumatologie, Geneva, Switzerland, 6Rheumatology & Clin Immunology, Inselspital Bern, Bern, Switzerland

    Background/Purpose: Since the end of 2009, an ultrasound scoring call SONAR has been implemented for RA patients as a routine tool in the SCQM registry…
  • Abstract Number: 2635 • 2012 ACR/ARHP Annual Meeting

    Exploring the Influence of Patient Perceptions On Medication Escalation in Daily Practice

    Jos Hendrikx1, Wietske Kievit2, Jaap Fransen2 and Piet L.C.M. van Riel2, 1Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: In rheumatoid arthritis (RA), patients' and physicians' perceptions of disease can differ and patients who are satisfied with their health do not tend to…
  • Abstract Number: 2509 • 2012 ACR/ARHP Annual Meeting

    Cost-Effectiveness of Training Rural Providers to Perform Joint Injections

    Michael J. Battistone1, Richard E. Nelson2, William D. Ashworth3, Andrea Barker3, Marissa Grotzke4, Timothy A. Huhtala5, Robert Z. Tashjian6 and Grant W. Cannon1, 1Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Division of Epidemiology, Salt Lake City VA and University of Utah, Salt Lake City, UT, 3General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, 4Division of Endocrinology, Salt Lake City VA and University of Utah, Salt Lake City, UT, 5Division of General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, 6Division of Orthopaedics, Salt Lake City VA and University of Utah, Salt Lake City, UT

    Background/Purpose: Community based outpatient clinics (CBOCs) have been established by the Department of Veteran Affairs (VA) to provide primary care services to veterans living in…
  • Abstract Number: 2463 • 2012 ACR/ARHP Annual Meeting

    Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis

    Josh J. Carlson1, Sarika Ogale2, Fred Dejonckheere3 and Sean Sullivan4, 1Pharmacy, University of Washington, Seattle, WA, 2Genentech, South San Francisco, CA, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Health Sciences Building, University of Washington, Seattle, WA

    Background/Purpose: The ADACTA trial found that biologic naïve patients with severe active RA who are methotrexate (MTX) intolerant or in whom continued MTX treatment is…
  • Abstract Number: 2440 • 2012 ACR/ARHP Annual Meeting

    Decisional Conflict Among Vulnerable Patient Populations with Rheumatoid Arthritis Is Associated with Limited Health Literacy and Non-English Language

    Laura Trupin1, Jennifer Barton1, Gina Evans-Young1, John B. Imboden1, Andrew J. Gross2, Dean Schillinger3 and Edward H. Yelin4, 1Rheumatology, UCSF, San Francisco, CA, 2Medicine, University of California, San Francisco, San Francisco, CA, 3Medicine and Center for Vulnerable Populations, UCSF, San Francisco, CA, 4Arthritis Research Group, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Suboptimal communication in shared decision-making among vulnerable populations has been reported in rheumatoid arthritis (RA). National and international recommendations for quality health care highlight…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology